Targeting Tn-positive tumors with an afucosylated recombinant anti-Tn IgG.
Targeting Tn-positive tumors with an afucosylated recombinant anti-Tn IgG.
复制标题
DOI：
10.1038/s41598-023-31195-6
复制
发表时间：
2023-03-28
影响因子：
4.6
通讯作者：
Cummings, Richard D.
中科院分区：
文献类型：
--
作者：
Matsumoto, Yasuyuki;Jia, Nan;Heimburg-Molinaro, Jamie;Cummings, Richard D.
The aberrant expression of the Tn antigen (CD175) on surface glycoproteins of human carcinomas is associated with tumorigenesis, metastasis, and poor survival. To target this antigen, we developed Remab6, a recombinant, human chimeric anti-Tn-specific monoclonal IgG. However, this antibody lacks antibody-dependent cell cytotoxicity (ADCC) effector activity, due to core fucosylation of its N-glycans. Here we describe the generation of an afucosylated Remab6 (Remab6-AF) in HEK293 cells in which the FX gene is deleted (FXKO). These cells cannot synthesize GDP-fucose through the de novo pathway, and lack fucosylated glycans, although they can incorporate extracellularly-supplied fucose through their intact salvage pathway. Remab6-AF has strong ADCC activity against Tn+ colorectal and breast cancer cell lines in vitro, and is effective in reducing tumor size in an in vivo xenotransplant mouse model. Thus, Remab6-AF should be considered as a potential therapeutic anti-tumor antibody against Tn+ tumors.
登录
查看更多内容
DOI：
10.1002/prca.201300024
发表时间：
2013-10
期刊：
Proteomics. Clinical applications
影响因子：
--
作者：
Ju T;Wang Y;Aryal RP;Lehoux SD;Ding X;Kudelka MR;Cutler C;Zeng J;Wang J;Sun X;Heimburg-Molinaro J;Smith DF;Cummings RD
通讯作者：
Cummings RD
影响因子：
158.5
作者：
Kobayashi, S;Boggon, TJ;Halmos, B
通讯作者：
Halmos, B
影响因子：
50.3
作者：
Anh Tuan Nguyen;Chia, Joanne;Bard, Frederic
通讯作者：
Bard, Frederic
影响因子：
5.2
作者：
Berois N;Pittini A;Osinaga E
通讯作者：
Osinaga E
影响因子：
4.1
作者：
Kanda, Yutaka;Imai-Nishiya, Harue;Satoh, Mitsuo
通讯作者：
Satoh, Mitsuo